{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Condition&page=20", "query": { "condition": "Skin Condition", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 16278, "total_pages": 1628, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Condition&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Condition&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T22:05:43.220Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01897441", "title": "Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stage IIA Breast Cancer", "Stage IIB Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytology Specimen Collection Procedure", "type": "OTHER" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Endocrine therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Albert Einstein College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2013-06", "completion_date": "2023-10-25", "has_results": true, "last_update_posted_date": "2024-12-24", "last_synced_at": "2026-10-23T22:05:43.220Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01897441" }, { "nct_id": "NCT00146770", "title": "Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Mucopolysaccharidosis I", "Hurler's Syndrome", "Hurler-Scheie Syndrome", "Scheie Syndrome" ], "interventions": [ { "name": "Aldurazyme", "type": "BIOLOGICAL" }, { "name": "placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 45, "start_date": "2001-05", "completion_date": "2005-03", "has_results": true, "last_update_posted_date": "2015-04-03", "last_synced_at": "2026-10-23T22:05:43.220Z", "location_count": 8, "location_summary": "Mobile, Alabama • Atlanta, Georgia • Rochester, New York + 5 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Rochester", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Toledo", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00146770" }, { "nct_id": "NCT03111186", "title": "Ibuprofen Plus Acetaminophen Versus Oxycodone Alone After Hand Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carpal Tunnel Syndrome", "Dupuytren Contracture", "Trigger Digit", "Ganglion Cysts", "De Quervain Disease" ], "interventions": [ { "name": "Oxycodone Hcl 5Mg", "type": "DRUG" }, { "name": "Ibuprofen 400 mg", "type": "DRUG" }, { "name": "Acetaminophen 650 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2017-04-24", "completion_date": "2019-05-01", "has_results": false, "last_update_posted_date": "2019-09-26", "last_synced_at": "2026-10-23T22:05:43.220Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03111186" }, { "nct_id": "NCT00087373", "title": "Vaccine Therapy in Treating Patients With Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "recombinant fowlpox-TRICOM vaccine", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2004-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-06-09", "last_synced_at": "2026-10-23T22:05:43.220Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00087373" }, { "nct_id": "NCT01189383", "title": "IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Melanoma Stage III", "Malignant Melanoma Stage IV" ], "interventions": [ { "name": "IL15-DC Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "21 Years to 75 Years" }, "enrollment_count": 20, "start_date": "2011-01", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2016-12-22", "last_synced_at": "2026-10-23T22:05:43.220Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01189383" }, { "nct_id": "NCT05628883", "title": "Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Melanoma", "Unresectable Melanoma", "Acral Melanoma", "Mucosal Melanoma", "Cutaneous Melanoma", "Ocular Melanoma", "Uveal Melanoma", "Iris Melanoma", "Conjunctival Melanoma", "Non-Cutaneous Melanoma" ], "interventions": [ { "name": "TBio-4101", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 17, "start_date": "2022-11-22", "completion_date": "2025-03-06", "has_results": false, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-10-23T22:05:43.220Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05628883" }, { "nct_id": "NCT01427166", "title": "Non-Invasive Imaging for Cording in Breast Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Non invasive venous ultrasound", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 5, "start_date": "2011-08", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2016-03-16", "last_synced_at": "2026-10-23T22:05:43.220Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01427166" }, { "nct_id": "NCT00307437", "title": "A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg", "type": "DRUG" }, { "name": "Ustekinumab (CNTO 1275) 45 mg", "type": "DRUG" }, { "name": "Ustekinumab (CNTO 1275) 90 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Centocor Research & Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1230, "start_date": "2005-05", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2013-01-24", "last_synced_at": "2026-10-23T22:05:43.220Z", "location_count": 28, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00307437" }, { "nct_id": "NCT04518995", "title": "Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alopecia Areata" ], "interventions": [ { "name": "CTP-543 matching placebo", "type": "DRUG" }, { "name": "CTP-543", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Concert Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 706, "start_date": "2020-11-23", "completion_date": "2022-04-19", "has_results": true, "last_update_posted_date": "2023-05-03", "last_synced_at": "2026-10-23T22:05:43.220Z", "location_count": 47, "location_summary": "Birmingham, Alabama • Bakersfield, California • Encinitas, California + 40 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04518995" }, { "nct_id": "NCT06400875", "title": "Observational Study to Investigate the Use of Sterilized Porcine Placental Tissue in the Treatment of Chronic VLU", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Ulcer Venous", "Wound Heal" ], "interventions": [ { "name": "InnovaMatrix® AC Sterilized, Porcine Placental Extracellular Matrix (ECM)", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "ConvaTec Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2023-07-10", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2025-05-29", "last_synced_at": "2026-10-23T22:05:43.220Z", "location_count": 1, "location_summary": "Cambridge, Massachusetts", "locations": [ { "city": "Cambridge", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06400875" } ] }